Immune Therapeutics (IMUN) Stock Price, News & Analysis

Company Overview

Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.

Key Stats

• Today's Range: $0.09 to $0.09
• 50-Day Range: $0.09 to $0.09
• 52-Week Range: $0.07 to $1.30
• Volume: 12 shs
• Average Volume: 15,246 shs
• Market Capitalization: $7.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMUN Stock Analysis - Frequently Asked Questions

How have IMUN shares performed this year?

Immune Therapeutics' stock was trading at $0.0930 at the beginning of 2025. Since then, IMUN shares have increased by 0.0% and is now trading at $0.0930.

How do I buy shares of Immune Therapeutics?

Shares of IMUN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Therapeutics investors own include Asia Broadband (AABB), CRISPR Therapeutics (CRSP), Edge Therapeutics (EDGE), Gilead Sciences (GILD), Northwest Biotherapeutics (NWBO), Galiano Gold (AKG) and Agritek (AGTK).

Company Calendar

• Today: 7/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IMUN
• CIK: 1559356
• Web: www.immunetherapeutics.com
• Phone: (888) 613-8802
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -544.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: -3.10

Miscellaneous

• Outstanding Shares: 83,660,000
• Free Float: 41,335,000
• Market Cap: $7.78 million
• Optionable: Not Optionable
• Beta: 0.46